The Single Use Bioprocessing
market industry is projected to grow from USD 10.27 Billion in 2023 to USD
46.56 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of
20.80% during the forecast period (2023 - 2032).
The single-use
bioprocessing market is experiencing robust growth, fueled by
increasing demand for flexible and cost-effective solutions in
biopharmaceutical production. With a focus on efficiency and reduced
contamination risk, single-use technologies offer advantages over traditional
stainless-steel systems. The market witnesses’ innovations in disposable
bioreactors, filtration systems, and mixers, catering to diverse bioprocessing
needs. Factors such as the rise in biopharmaceutical R&D, expansion of
biomanufacturing facilities, and regulatory support further drive market
expansion. Additionally, the COVID-19 pandemic has accelerated adoption,
highlighting the adaptability and scalability of single-use bioprocessing
solutions. Key players continue to invest in R&D to enhance product
offerings and meet evolving industry requirements.
The single-use bioprocessing
market has witnessed significant growth in recent years, driven by the
increasing adoption of bioprocessing containers in various biopharmaceutical
and biotechnology applications. Bioprocessing containers offer a flexible and
cost-effective solution compared to traditional stainless-steel systems,
catering to the evolving needs of the industry.
These containers play a crucial
role in single-use bioprocess setups, facilitating the storage, transport, and
handling of biopharmaceutical materials such as cell cultures, media, and
buffers. The convenience, reduced risk of cross-contamination, and elimination
of cleaning and validation processes associated with single-use systems have
propelled their popularity among biomanufacturers.
The demand for bioprocessing
containers is further fueled by factors such as the growing focus on
operational efficiency, scalability, and the increasing trend towards
personalized medicine and biologics manufacturing. As biopharmaceutical
companies strive to streamline their production processes and accelerate
time-to-market, single-use bioprocessing containers emerge as indispensable
tools.
Moreover, stringent regulatory
guidelines and the emphasis on product quality and safety drive the adoption of
single-use systems in bioprocessing. Companies offering bioprocessing
containers continually innovate to enhance product performance, reliability,
and compatibility with different bioprocessing workflows, thereby expanding
their market presence and catering to diverse customer requirements.
Segment Analysis
The single-use bioprocessing
market has been segmented based on product, application, end-user, and
workflow.
On the basis of product, the
market is segmented into filtration assemblies, disposable bioreactors,
disposable mixers, media bags & containers, and others. The media bags
& containers segment was attributed to holding the largest market share in
2022 because media bag and container use in the biopharmaceutical business
reduces capital expenditure, waste generation, and operational expenses.
Based on application, the
single-use bioprocessing market has been segmented into filtration,
purification, cell culture, and others. The filtration segment was expected to
hold market dominance in 2022 due to single-use bioprocessing systems are
gaining popularity for use in filtration since they filter even when used in
huge quantities. It can be ultra-filtered, utilized to smooth out biomolecules
and reduce bio-burden.
Based on end-users, the
single-use bioprocessing market has been segmented into biopharmaceutical
manufacturers, clinical & academic research institutes, and others. The
biopharmaceutical manufacturers segment was expected to hold market dominance
in 2022 because high expansion can be attributed to a number of factors,
including the increasing commercial success of biologics and the consequent
rise in contract manufacturing services.
Regional Analysis
The single-use bioprocessing
market, based on region, has been divided into North America, Europe,
Asia-Pacific, and the Rest of the World. North America consists of the US and
Canada. The European Single Use Bioprocessing market comprises Germany, France,
the UK, Italy, Spain, and the Rest of Europe. The Single Use Bioprocessing
market in Asia-Pacific has been segmented into China, India, Japan, Australia,
South Korea, and the Rest of Asia-Pacific. The Rest of the World Single Use
Bioprocessing market comprises the Middle East, Africa, and Latin America.
The North American regional
sector maintained the largest market share for single-use bioprocessing. This
increase is attributed to rising demand for biopharmaceuticals in light of
aging populations and a greater emphasis on high-quality healthcare; bio-manufacturers
are expanding their facilities. Single-use bioprocessing systems have seen a
rise in popularity due to their convenience, low price, and the advent of new
technology in this region.
Moreover, the European market has
been persistently growing over the forecast period. The demand for single-use
bioprocessing is driven by the growing healthcare infrastructure, vast numbers
of manufacturers, rising disposable product sales, rising healthcare costs, an
already-developed healthcare infrastructure, and positive reimbursement
policies in healthcare all contribute to the expansion of this industry.
Additionally, due to the high
demand, there is increased usage of single-usage gadgets. The pharmaceutical
and laboratory equipment markets have expanded quickly in Asia and the Pacific,
creating promising new prospects for single-use bioprocessing goods. Asia
Pacific is anticipated to experience the quickest growth over the forecast
period.
Key Players:
The Single
Use Bioprocessing Companies are Thermo Fisher Scientific Inc., Sartorius
AG, Merck KGaA, Pall Corporation, Corning Incorporated, Eppendorf AG, General
Electric Company (GE Healthcare), Lonza, Rentschler Biopharma SE, JM
BioConnect, Meissner Filtration Products, Inc., Infors AG, Boehringer Ingelheim
GmbH, Entegris, Inc., and PBS Biotech Inc.
Related Reports:
Spinal Cord Stimulator
Diagnostic Electrocardiograph
Peripheral Artery Disease
Patient Blood Management
Adhesion Barrier
For More Information, Please
Visit @ Market
Research Future
Comments
Post a Comment